Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

被引：0
|
作者：
Denker, S. [1 ,2 ]
Bittner, A. [1 ,2 ]
Frick, M. [1 ]
Kase, J. [1 ]
Hoffmann, J. [3 ]
Trenker, C. [3 ]
Keller, U. [2 ,4 ,5 ,6 ,7 ]
Bogner, C. [8 ]
Huttmann, A. [9 ]
Duhrig, J. [9 ]
Janz, M. [4 ,7 ]
Mathas, S. [4 ,7 ]
Marks, R. [10 ,11 ]
Krohn, U. [10 ,11 ]
Bhattacharya, A. [4 ]
Na, I. -K [1 ,2 ]
Gebauer, B. [4 ]
Savic, L. J. [4 ]
Hubner, N. [7 ]
Akalin, A. [12 ]
Eils, R. [2 ]
Bullinger, L. [1 ,2 ,5 ,6 ]
Schmitt, C. A. [1 ,7 ,13 ]
机构：
[1] Charite Univ Med Berlin, Med Klin mS Hamatol Onkol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany
[2] Berlin Inst Hlth BIH, Berlin, Germany
[3] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol, Oncol,Immunol, Marburg, Germany
[4] Charite Univ Med Berlin, Berlin, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
[6] German Canc Consortium DKTK, Heidelberg, Germany
[7] Max Delbruck Ctr Mol Med, Berlin, Germany
[8] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany
[9] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hamatol, Essen, Germany
[10] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Fac Med, Freiburg, Germany
[11] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Med Ctr, Freiburg, Germany
[12] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Bioinformat & Omics Data Sci Platform, Berlin, Germany
[13] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V104
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [31] FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab plus Lenalidomide plus R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
    Vitolo, Umberto
    Nowakowski, Grzegorz S.
    Burke, John M.
    Fox, Christopher P.
    Trneny, Marek
    Chiappella, Annalisa
    Tillmanns, Sascha
    Sporchia, Andrea
    Brugger, Wolfram
    Lenz, Georg
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S376 - S377
  • [32] Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
    Till, Brian G.
    Li, Hongli
    Bernstein, Steven H.
    Fisher, Richard I.
    Burack, W. Richard
    Rimsza, Lisa M.
    Floyd, Justin D.
    DaSilva, Marco A.
    Moore, Dennis F., Jr.
    Pozdnyakova, Olga
    Smith, Sonali M.
    LeBlanc, Michael
    Friedberg, Jonathan W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (02) : 208 - 218
  • [33] Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
    Nowakowski, Grzegorz S.
    Willenbacher, Wolfgang
    Greil, Richard
    Larsen, Thomas Stauffer
    Patel, Krish
    Jager, Ulrich
    Manges, Robert F.
    Trumper, Lorenz H.
    Haioun, Corinne
    Everaus, Hele
    Kalakonda, Nagesh
    Knoble, Jeanna
    Brown, Peter
    Joergensen, Judit Meszaros
    Cunningham, David
    Domper, Neus
    Casadebaig, Marie-Laure
    Manzke, Oliver
    Munoz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
    Yuqin Song
    Hui Zhou
    Huilai Zhang
    Wei Liu
    Yuerong Shuang
    Keshu Zhou
    Fangfang Lv
    Hao Xu
    Jianfeng Zhou
    Wei Li
    Huaqing Wang
    Hongyu Zhang
    Haiwen Huang
    Qingyuan Zhang
    Wei Xu
    Zheng Ge
    Ying Xiang
    Shuye Wang
    Da Gao
    Shun’e Yang
    Jinying Lin
    Lin Wang
    Liqun Zou
    Meifang Zheng
    Jing Liu
    Zonghong Shao
    Ying Pang
    Ruixiang Xia
    Zhendong Chen
    Ming Hou
    Hongxia Yao
    Ru Feng
    Zhen Cai
    Mingzhi Zhang
    Wenhua Ran
    Lin Liu
    Shan Zeng
    Wei Yang
    Peng Liu
    Aibin Liang
    Xuelan Zuo
    Qingfeng Zou
    Junxun Ma
    Wei Sang
    Ye Guo
    Wei Zhang
    Yongqing Cao
    Yan Li
    Jifeng Feng
    Xin Du
    Advances in Therapy, 2021, 38 : 1889 - 1903
  • [35] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
    Song, Yuqin
    Zhou, Hui
    Zhang, Huilai
    Liu, Wei
    Shuang, Yuerong
    Zhou, Keshu
    Lv, Fangfang
    Xu, Hao
    Zhou, Jianfeng
    Li, Wei
    Wang, Huaqing
    Zhang, Hongyu
    Huang, Haiwen
    Zhang, Qingyuan
    Xu, Wei
    Ge, Zheng
    Xiang, Ying
    Wang, Shuye
    Gao, Da
    Yang, Shun'e
    Lin, Jinying
    Wang, Lin
    Zou, Liqun
    Zheng, Meifang
    Liu, Jing
    Shao, Zonghong
    Pang, Ying
    Xia, Ruixiang
    Chen, Zhendong
    Hou, Ming
    Yao, Hongxia
    Feng, Ru
    Cai, Zhen
    Zhang, Mingzhi
    Ran, Wenhua
    Liu, Lin
    Zeng, Shan
    Yang, Wei
    Liu, Peng
    Liang, Aibin
    Zuo, Xuelan
    Zou, Qingfeng
    Ma, Junxun
    Sang, Wei
    Guo, Ye
    Zhang, Wei
    Cao, Yongqing
    Li, Yan
    Feng, Jifeng
    Du, Xin
    ADVANCES IN THERAPY, 2021, 38 (04) : 1889 - 1903
  • [36] AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R- CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Hawkes, Eliza A.
    Manos, Kate
    Smith, Charmaine
    Hawking, Joanne
    O'Brien, Stephanie
    Churilov, Leonid
    McKendrick, Joseph
    Renwick, William
    Grigg, Andrew
    Witkowski, Tom
    Scott, Andrew
    Lee, Sze-Ting
    Lin, Wendi
    Fong, Chun
    Rooney, Carmela
    Barraclough, Allison
    Wight, Joel
    Chong, Geoff
    BLOOD, 2019, 134
  • [37] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
  • [38] Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.
    Nowakowski, Grzegorz S.
    Chiappella, Annalisa
    Witzig, Thomas E.
    Spina, Michele
    Zhang, Lei
    Flament, Jocelyne
    Repici, Jacqueline
    Vitolo, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lLymphoma (DLBCL) overcomes Bcl2-associated chemotherapy resistance.
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Gaulard, P
    Lederlin, P
    Sebban, C
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Coiffier, B
    BLOOD, 2002, 100 (11) : 161A - 161A
  • [40] frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab plus Lenalidomide plus R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
    Vitolo, Umberto
    Nowakowski, Grzegorz S.
    Burke, John M.
    Fox, Christopher P.
    Trneny, Marek
    Chiappella, Annalisa
    Waldron-Lynch, Maeve
    Hadar, Nira
    Pachori, Alok
    Lenz, Georg
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S352 - S353
12345